
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult a stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant, or other professional adviser.

If you have sold or transferred all your shares in Hua Xia Healthcare Holdings Limited (the “Company”), you should at once hand this circular and the accompanying form of proxy to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

**HUA XIA HEALTHCARE HOLDINGS LIMITED****華夏醫療集團有限公司****(incorporated in the Cayman Islands with limited liability)***(Stock Code: 8143)**

- (1) PROPOSED GENERAL MANDATES TO ISSUE
AND REPURCHASE SHARES;
(2) PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT;
(3) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
AND
(4) NOTICE OF ANNUAL GENERAL MEETING**

A notice convening the annual general meeting (the “AGM”) of the Company to be held at 19/F., New Wing, 101 King’s Road, Hong Kong on Monday, 17 August 2015 at 3:30 p.m. is set out on pages 21 to 26 of this circular. A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the AGM, you are requested to complete the form of proxy in accordance with the instruction printed thereon and return the same to the principal place of business of the Company in Hong Kong at 19/F., New Wing, 101 King’s Road, Hong Kong as soon as possible but in any event not less than 48 hours before the time appointed for the holding of the AGM. Completion and return of the enclosed form of proxy will not preclude you from attending and voting in person at such meeting or any adjournment meeting should you so wish.

This circular will remain on the “Latest Company Announcements” page of the GEM website at www.hkgem.com for at least 7 days from the date of its posting and the website of the Company at www.huaxia-healthcare.com.

23 July 2015

* For identification purpose only

CHARACTERISTICS OF GEM

GEM has been positioned as a market designed to accommodate companies to which a higher investment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors.

Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board of the Stock Exchange and no assurance is given that there will be a liquid market in the securities traded on GEM.

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	
INTRODUCTION	4
(1) PROPOSED GENERAL MANDATE TO ISSUE AND REPURCHASE SHARES	5
(2) PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT	6
(3) RE-ELECTION OF RETIRING DIRECTORS	9
(4) ANNUAL GENERAL MEETING	10
GEM LISTING RULES REQUIREMENT FOR VOTING	10
SHAREHOLDERS ABSTAIN FROM VOTING	10
RESPONSIBILITY STATEMENT	10
RECOMMENDATIONS	11
GENERAL	11
APPENDIX I – EXPLANATORY STATEMENT	12
APPENDIX II – DETAILS OF THE RETIRING DIRECTORS PROPOSED TO BE RE-ELECTED	17
NOTICE OF ANNUAL GENERAL MEETING	20

DEFINITIONS

In this circular, the following expression shall have the following meanings unless the context otherwise requires:

“AGM”	the annual general meeting of the Company to be held at 19/F., New Wing, 101 King’s Road, Hong Kong on Monday, 17 August 2015, at 3:30 p.m.
“Articles of Association”	articles of association of the Company adopted pursuant to the written resolutions of the then shareholders of the Company passed on 20 April 2002 and as amended from time to time
“associates”	have the same meaning as prescribed in the GEM Listing Rules
“Board”	board of Directors
“Company”	Hua Xia Healthcare Holdings Limited, a company incorporated in the Cayman Islands with limited liability, the issued Shares of which are listed on GEM of the Stock Exchange
“Companies Law”	the companies law, Chapter 22 (Laws of 1961, as consolidated and revised) of the Cayman Islands
“Director(s)”	the director(s) of the Company
“GEM”	the Growth Enterprise Market of the Stock Exchange
“GEM Listing Rules”	the Rules Governing the Listing of Securities on GEM
“General Mandate”	the general mandate proposed to be granted to the Directors at the AGM to allot, issue and deal with new Shares not exceeding 20% of the number of issued Shares as at the date of the AGM which is to be extended by the number of Shares purchased pursuant to the Repurchase Mandate
“Group”	the Company and its subsidiaries

DEFINITIONS

“Hong Kong”	the Hong Kong Special Administrative Region of the People’s Republic of China
“Latest Practicable Date”	22 July 2015, being the latest practicable date prior to the printing of this circular for ascertaining certain information contained herein
“Old Share Option Scheme”	the share option scheme adopted by the Company on 20 April 2002 which has been expired
“Option(s)”	any options granted under the Share Option Scheme and the Old Share Option Scheme conferring a right to subscribe for shares
“Optionholders”	the relevant holders of the Options
“Participants”	full time or part time employees of the Group (including any directors, whether executive or non-executive and whether independent or not, of the Company or any subsidiary) and any suppliers, consultants, agents and advisers or any person who, in the sole discretion of the Board, has contributed or may contribute to the Group eligible for Options under the Share Option Scheme
“PRC”	the People’s Republic of China, which for the purpose of this circular excludes Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
“Repurchase Mandate”	a general and unconditional mandate to be granted to the Directors at the AGM to exercise all powers of the Company to repurchase Shares up to a maximum of 10% of the issued share capital of the Company as at the date of passing of the relevant resolution granting such mandate
“Scheme Mandate Limit”	the maximum number of Shares which may be issued upon exercise of all of the Options which shall not in aggregate exceed 10% of the Shares in issue at the date of approval of the refreshed limit by the Shareholders

DEFINITIONS

“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)
“Shareholder(s)”	holder(s) of the Shares
“Share Option Scheme”	the share option scheme adopted by the Company on 10 August 2011
“Shares”	ordinary shares of HK\$0.01 each in the issued share capital of the Company
“Stock Exchange”	the Stock Exchange of Hong Kong Limited
“Takeovers Code”	the Hong Kong Code on Takeovers and Mergers
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“%”	per cent

LETTER FROM THE BOARD



HUA XIA HEALTHCARE HOLDINGS LIMITED

華夏醫療集團有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

Executive Directors:

Dr. Jiang Tao (*Chief Executive Officer*)
Mr. Zheng Gang
Dr. Huang Jiaqing
Mr. Yung Ka Chun

Non-executive Directors:

Dr. Wong Yu Man, James
Mr. Tang Xun

Independent non-executive Directors:

Ms. Wong Ka Wai, Jeanne
Prof. Hu Shanlian
Prof. Lu Chuanzhen

Registered office:

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

*Head office and principal place of
business in Hong Kong:*

19th Floor, New Wing
101 King's Road
Hong Kong

23 July 2015

*To Shareholders of the Company, and for information only,
holder(s) of Options, convertible notes and convertible preference shares*

Dear Sir or Madam,

- (1) PROPOSED GENERAL MANDATES TO ISSUE
AND REPURCHASE SHARES;
(2) PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT;
(3) PROPOSED RE-ELECTION OF RETIRING DIRECTORS;
AND
(4) NOTICE OF ANNUAL GENERAL MEETING**

INTRODUCTION

The purpose of this circular is to provide you with information regarding certain resolutions to be proposed at the forthcoming AGM of the Company to be held on Monday, 17 August 2015 at 3:30 p.m. including but not limited to (i) ordinary resolutions relating to the grant of General Mandate and Repurchase Mandate to the Directors for the issue and repurchase of its Shares; (ii) ordinary resolution relating to the approval of refreshment of the Scheme Mandate Limit on grant of Options under the Share Option Scheme; and (iii) ordinary resolution relating to the re-election of the retiring Directors.

* For identification purpose only

LETTER FROM THE BOARD

(1) PROPOSED GENERAL MANDATE TO ISSUE AND REPURCHASE SHARES

The existing general mandate granted to the Directors to allot and issue new Shares and to repurchase Shares at the annual general meeting of the Company held on 29 September 2014 will lapse at the conclusion of the AGM.

At the AGM, ordinary resolutions will be proposed to the Shareholders (a) approving the grant of the General Mandate to the Directors to allot, issue and otherwise deal in the new Shares not exceeding 20% of the aggregate nominal amount of the share capital of the Company in issue as at the date of passing such resolution; (b) approving the grant of the Repurchase Mandate to the Directors to repurchase, inter alia, Shares, the aggregate nominal amount of which does not exceed 10% of the aggregate nominal amount of the issued share capital of the Company as at the date of passing such resolution; and (c) adding to the number of Shares which may be allotted, issued or dealt in under the General Mandate the amount of any Shares repurchased by the Company under the Repurchase Mandate.

The General Mandate

Under the General Mandate, the Directors will be given a general mandate to allot, issue and deal in the new Shares representing not more than 20% of the issued share capital of the Company outstanding as at the conclusion of the AGM.

As at the Latest Practicable Date, the Company had an aggregate of 1,698,769,944 Shares in issue. Subject to the passing of the ordinary resolution for the approval of the General Mandate and assuming that no Shares will be issued or repurchased by the Company between the Latest Practicable Date and the date of the AGM, the Company would be allowed under the General Mandate to allot, issue and deal in up to a maximum of 339,753,988 new Shares.

The Repurchase Mandate

It is also proposed that the Repurchase Mandate be granted to the Directors. The explanatory statement required by the GEM Listing Rules to be sent to the Shareholders in connection with the proposed Repurchase Mandate is set out on pages 12 to 17 of this circular.

The Directors wish to state that they have no present intention to repurchase any Shares.

LETTER FROM THE BOARD

Extension of the General Mandate

Subject to the approval of the Repurchase Mandate, another ordinary resolution will be proposed at the AGM to add to the limit under the General Mandate the amount of any Shares repurchased by the Company pursuant to the Repurchase Mandate.

Effectiveness of General Mandate and Repurchase Mandate

The General Mandate and the Repurchase Mandate shall be effective until whichever is the earliest of:

- (a) the conclusion of the next annual general meeting of the Company; or
- (b) the expiration of the period within which the next annual general meeting of the company is required by the Articles of Association, or any applicable law of the Cayman Islands to be held; or
- (c) the passing of an ordinary resolution by the Shareholders in a general meeting revoking or varying the authority given to the Directors.

(2) PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT

The Company adopted the Share Option Scheme by Shareholders' approval at the annual general meeting held on 10 August 2011.

At present, the Company has no other share option scheme apart from the Share Option Scheme. As at the Latest Practicable Date, a total of 67,071,991 Options were outstanding, representing approximately 3.95% of the issued share capital of the Company, all of which were granted under the Old Share Option Scheme and Share Option Scheme. Breakdown setting out the number of Options outstanding, their respective exercise price and their respective exercise period under Old Share Option Scheme and Share Option Scheme as at the Latest Practicable Date are as follows:

LETTER FROM THE BOARD

Old Share Option Scheme

Categories of grantees	Exercise period	Exercise price	Number of Options outstanding
Directors			
Employees and consultants of the Group	13 July 2006 to 12 July 2016	HK\$3.61	459,738
	21 March 2007 to 20 March 2017	HK\$2.94	1,042,253
	30 September 2009 to 29 March 2019	HK\$0.50	450,000
			1,951,991
Total Options outstanding under the Old Share Option Scheme			1,951,991

Share Option Scheme

Categories of grantees	Exercise period	Exercise price	Number of Options outstanding
Directors			
Dr. Jiang Tao	18 April 2015 to 17 April 2018	HK\$0.68	4,410,000
Mr. Zheng Gang	18 April 2015 to 17 April 2018	HK\$0.68	4,410,000
Mr. Yung Ka Chun	18 April 2015 to 17 April 2018	HK\$0.68	3,960,000
Mr. Huang Jiaqing	18 April 2015 to 17 April 2018	HK\$0.68	4,200,000
Dr. Wong Yu Man James	18 April 2015 to 17 April 2018	HK\$0.68	1,000,000
Mr. Tang Xun	18 April 2015 to 17 April 2018	HK\$0.68	3,000,000
Employees of the Group	18 April 2015 to 17 April 2018	HK\$0.68	44,140,000
Total Options outstanding under the Share Option Scheme			65,120,000
Total Options outstanding			67,071,991

LETTER FROM THE BOARD

The Scheme Mandate Limit, as refreshed in 2014 at the annual general meeting of the Company held on 29 September 2014, allowed the Directors to grant Options to subscribe for up to 115,738,826 Shares. A total of 100,000,000 Options were granted to Participants on 16 April 2015. None of these Participants has been granted with Options exceeding the limit of 1% of the issued capital of the Company as set out in Rule 23.03 of the GEM Listing Rules. No further grant of Options has been made since then. As at the Latest Practicable Date, the Company might only make further grant of Options to subscribe up to 15,738,826 Shares, in accordance with the existing Scheme Mandate Limit.

The remaining existing Scheme Mandate Limit will lapse upon the approval of refreshment thereof at the AGM. Under the rules of the Share Option Scheme and subject to the GEM Listing Rules:

- (i) the initial limit on the maximum number of Shares that may be issued upon the exercise of the Options shall not exceed 10% of the shares of the Company in issue as at the date of approval of the Share Option Scheme;
- (ii) the Company may seek Shareholders' approval to refresh the Scheme Mandate Limit on the grant of Options under the Share Option Scheme as and when required. However, the Scheme Mandate Limit as refreshed shall not exceed 10% of the Shares in issue as at the date of the aforesaid Shareholders' approval. Options previously granted under the Share Option Scheme and other share option schemes (including those outstanding, cancelled, lapsed in accordance with the Share Option Scheme or exercised Options) will not be counted for the purpose of calculating the Scheme Mandate Limit as refreshed. A circular must be sent to Shareholders in connection with the meeting at which their approval will be sought;
- (iii) the Company may seek separate approval by the Shareholders in a general meeting to grant Options beyond the Scheme Mandate Limit only to Participants specifically identified by the Company before the aforesaid Shareholders' meeting where such approval is sought; and
- (iv) the overall limit on the number of Shares which may be issued upon the exercise of all outstanding Options granted and yet to be exercised under the Share Option Scheme and any other option schemes of the Company must not in aggregate exceed 30% of the total number of Shares in issue from time to time.

LETTER FROM THE BOARD

As at the Latest Practicable Date, the Company has 67,071,991 Options outstanding, representing approximately 3.95% of the entire issued share capital of the Company. The Directors consider that the Company should refresh the Scheme Mandate Limit so that the Company could have more flexibility to provide incentives to Participants by way of granting Options to them. If the Scheme Mandate Limit is again refreshed on the basis of 1,698,769,944 Shares in issue as at the Latest Practicable Date and assuming that no Shares are issued or repurchased by the Company prior to the AGM, the Company will be allowed to grant further Options under the Share Option Scheme of the Company carrying rights to subscribe for a maximum of 169,876,994 Shares (being 10% of the issued share capital of the Company as at the date of the AGM at which the refreshed limit is approved). In this regard, the Company will seek approval from the Shareholders in the AGM to refresh the Scheme Mandate Limit. The proposed refreshment of the Scheme Mandate Limit will be conditional upon (i) the Listing Committee of GEM granting the listing of, and the permission to deal in, such number of Shares, representing 10% of the Shares in issue as at the date of the AGM which may fall to be allotted and issued pursuant to the exercise of the Options granted under the refreshed Scheme Mandate Limit; and (ii) the passing of an ordinary resolution by the Shareholders at the AGM to approve the refreshment of the Scheme Mandate Limit. Application will be made to the Stock Exchange for the listing of and permission to deal in the Shares to be issued pursuant to the exercise of the Options granted under the Share Option Scheme up to the refreshed Scheme Mandate Limit.

As at the Latest Practicable Date, other than the Share Option Scheme, the Company has no other share option scheme in force. The Directors consider that the refreshment of the Scheme Mandate Limit is in the interests of the Group and the Shareholders as a whole. The refreshment of the Scheme Mandate Limit is in line with the purpose of the Share Option Scheme and is in compliance with Chapter 23 of the GEM Listing Rules.

(3) RE-ELECTION OF RETIRING DIRECTORS

In accordance with the Articles of Association, Mr. Yung Ka Chun, Dr. Wong Yu Man, James and Mr. Tang Xun shall retire from their offices at the AGM and, being eligible, will offer themselves for re-election.

Details of the Directors who are proposed to be re-elected at the AGM are set out in Appendix II to this circular.

LETTER FROM THE BOARD

(4) ANNUAL GENERAL MEETING

A notice convening the AGM of the Company to be held at 19/F., New Wing, 101 King's Road, Hong Kong on Monday, 17 August 2015 at 3:30 p.m. is set out in this circular. A form of proxy for the AGM is enclosed with this circular. Whether or not you are able to attend the AGM in person, please complete and return the form of proxy in accordance with the instructions printed thereon to the principal place of business of the Company in Hong Kong at 19/F., New Wing, 101 King's Road, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for holding of the AGM. Completion and return of the form of proxy will not preclude you from attending and voting at the AGM or any adjourned meeting (as the case may be) should you so wish.

GEM LISTING RULES REQUIREMENT FOR VOTING

Pursuant to Rule 17.47(4) of the GEM Listing Rules, vote of shareholders at a general meeting must be taken by poll. Accordingly, all resolutions will be put to vote by way of poll at the AGM. An announcement on the poll vote results will be made by the Company after the AGM in the manner prescribed under Rule 17.47(5) of the GEM Listing Rules.

SHAREHOLDERS ABSTAIN FROM VOTING

None of the Shareholders is required to abstain from voting in respect of the resolutions to be proposed at the AGM.

RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

LETTER FROM THE BOARD

RECOMMENDATIONS

The Directors consider that (i) the general mandates to the Directors for the issue and repurchase of Shares; (ii) the refreshment of the Scheme Mandate Limit for the grant of Options under the Share Option Scheme; and (iii) the re-election of the retiring Directors are in interests of the Company and its Shareholders as a whole. Accordingly, the Directors recommend all Shareholders to vote in favour of the relevant resolutions to be proposed at the forthcoming AGM.

GENERAL

As at the Latest Practicable Date, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, none of the Directors, or the controlling Shareholder or the management Shareholders (as defined in the GEM Listing Rules) or their respective close associates had any interests in a business which competes or may compete with the business of the Group and have any other conflicts of interest with the Group.

By order of the Board
Hua Xia Healthcare Holdings Limited
Jiang Tao
Chief Executive Officer

This is an explanatory statement given to all Shareholders of the Company relating to the resolution to be proposed at the AGM authorising the Repurchase Mandate. It contains all the relevant information required pursuant to Rule 13.08 of the GEM Listing Rules which is set out as follows:

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 1,698,769,944 Shares of HK\$0.01 each.

Subject to the passing of the resolution in relation to the Repurchase Mandate and on the basis that no Shares are issued or repurchased by the Company prior to the AGM, the Company will be allowed under the Repurchase Mandate to repurchase a maximum of 169,876,994 Shares equivalent to approximately 10% of the issued share capital of the Company. The repurchased Shares will be cancelled and the Company's issued share capital will be reduced accordingly by the nominal value of the Shares repurchased.

2. EXERCISE OF THE REPURCHASE MANDATE

Exercise in full of the Repurchase Mandate, on the basis of 1,698,769,944 Shares of the Company in issue as at the Latest Practicable Date, could result in up to 169,876,994 Shares listed on GEM or on another stock exchange recognised by the Securities and Futures Commission and the Stock Exchange under the Code on Share Repurchases being repurchased by the Company during the period up to (i) the conclusion of the next annual general meeting of the Company after the AGM; (ii) the expiration of the period within which the next annual general meeting of the Company after the AGM is required by the Articles of Association or the Companies Law or any other applicable laws of the Cayman Islands to be held; or (iii) the revocation, variation or renewal of the repurchase mandate by ordinary resolution of the Shareholders in a general meeting, whichever occurs first.

3. REASONS FOR REPURCHASES

Although the Directors have no present intention to repurchase any Shares, they believe that the Repurchase Mandate will provide the Company the flexibility to make such repurchases when appropriate and is beneficial to the Company and the Shareholders. Such repurchases may, depending on market conditions and funding arrangements at the relevant time, lead to an enhancement of the net asset value of the Company and/or earning per Share.

4. FUNDING OF REPURCHASES

Repurchase of Shares will be funded out of funds legally available for such purpose in accordance with the Memorandum and Articles of Association of the Company and the applicable laws and regulations of the Cayman Islands.

The Company may not purchase its own securities on the GEM for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

5. EFFECT OF EXERCISING THE REPURCHASE MANDATE

There might be a material adverse impact on the working capital or the gearing position of the Group as compared with the position disclosed in the audited financial statements for the year ended 31 March 2015, being the date to which the latest published audited financial statements of the Company were made up, in the event that the Repurchase Mandate is exercised in full. However, the Directors do not propose to exercise the Repurchase Mandate to such an extent as it would, in the circumstances, have a material adverse effect on the working capital requirements of the Group or on the gearing positions which in the opinion of the Directors are from time to time appropriate for the Group. The number of Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regard to the circumstances then prevailing.

6. SHARE PRICES

The highest and lowest prices at which Shares have been traded on GEM in each of the past twelve months preceding the Latest Practicable Date were as follows:

	Price per Share	
	Highest <i>HK\$</i>	Lowest <i>HK\$</i>
2014		
July	0.540	0.450
August	0.500	0.405
September	0.710	0.445
October	0.820	0.580
November	0.770	0.570
December	0.630	0.450
2015		
January	0.650	0.385
February	0.610	0.510
March	0.650	0.520
April	2.080	0.580
May	2.050	1.200
June	1.780	1.050
July (up to the Latest Practicable Date)	1.190	0.420

7. UNDERTAKING OF THE DIRECTORS

The Directors have undertaken to the Stock Exchange that they will exercise the power of the Company to make repurchases pursuant to the proposed resolution in accordance with the GEM Listing Rules and the applicable laws of Hong Kong and in accordance with the regulations set out in the Memorandum and Articles of Association of the Company and also any applicable laws of the Cayman Islands.

None of the Directors nor, to the best of the knowledge and belief of the Directors having made all reasonable enquires, any of the close associates (as defined in the GEM Listing Rules) of any of the Directors has any present intention, in the event that the proposed Repurchase Mandate is approved by the Shareholders, to sell Shares to the Company.

As at the Latest Practicable Date, no core connected person (as defined in the GEM Listing Rules) of the Company has notified the Company that he/she has a present intention to sell Shares to the Company nor has he/she undertaken not to sell any of the Shares held by him/her to the Company in the event that the Company is authorised to make repurchases of Shares.

8. THE HONG KONG CODE ON TAKEOVERS AND MERGERS

If as a result of a Share repurchase, a shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition for the purpose of Rule 32 of the Takeovers Code. Accordingly, a shareholder or group of shareholders acting in concert, could obtain or consolidate control of the Company and become obliged to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code.

As at the Latest Practicable Date, the register of the substantial shareholders maintained by the Company under section 336 of the SFO showed that the following parties had interests in the Shares representing 10% or more of the voting power at any general meeting of the Company:

Name of Shareholder	Number of Shares	Position	Capacity	Approximate percentage of the total issued Shares	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Marshal International Investments Limited ("Marshal") (Note 1)	516,991,516	Long	Corporate interest	30.43%	33.81%
Easeglory Holdings Limited ("Easeglory") (Note 1)	516,991,516	Long	Beneficial owner	30.43%	33.81%
Yung Kwok Leong ("Mr. KL Yung") (Note 1)	516,991,516 1,700,000	Long Long	Corporate interest Personal interest	30.43% 0.10%	33.81% 0.11%
Mrs. Yung Muk Ying (Note 1)	518,691,516	Long	Interest of spouse	30.53%	33.92%
Yung Ka Chun ("Mr. KC Yung") (Note 2)	516,991,516 6,600,000	Long Long	Corporate interest Personal interest	30.43% 0.39%	33.81% 0.43%
South Hoper Industry Co. Ltd. [#] (南方希望實業有限公司) (Note 3)	343,217,539	Long	Corporate interest	20.20%	22.45%
New Hope Group Co. Ltd. [#] (新希望集團有限公司) (Note 3)	343,217,539	Long	Corporate interest	20.20%	22.45%

Name of Shareholder	Number of Shares	Position	Capacity	Approximate percentage of the total issued Shares	Approximate percentage of shareholding if the Repurchase Mandate is exercised in full
Tibet Hengyefeng Industrial Co., Ltd. [#] (西藏恒業峰實業有限公司) (Note 3)	343,217,539	Long	Corporate interest	20.20%	22.45%
New Hope International (Hong Kong) Limited (Note 3)	343,217,539	Long	Beneficial owner	20.20%	22.45%
Mr. Liu Yonghao (Note 3)	343,217,539	Long	Corporate interest	20.20%	22.45%
Ms. Liu Chang (Note 3)	343,217,539	Long	Corporate interest	20.20%	22.45%
Ms. Li Wei (Note 3)	343,217,539	Long	Corporate interest	20.20%	22.45%

[#] *The English translation of Chinese name(s) in this Circular, where indicated, is included for information only, and should not be regarded as the official English name(s) of such Chinese name(s).*

Notes:

- Easeglory is interested in 418,491,516 Shares and 98,500,000 convertible preference shares of the Company. The issued share capital of Easeglory is 100% beneficially owned by Marshal and the issued share capital of Marshal is 100% beneficially owned by Mr. KL Yung. He is also interested in 1,700,000 Shares and beneficially held by him in personal capacity. By virtue of her being the spouse of Mr. KL Yung, Mrs. Yung is deemed to be interested in 418,491,516 Shares and 98,500,000 convertible preference shares held by Easeglory and 1,700,000 Shares beneficially held by Mr. KL Yung in personal capacity.

Pursuant to the terms and conditions of the convertible preference shares, holder(s) of the convertible preference shares shall have the right to convert the convertible preference shares provided that any conversion of the convertible preference shares (i) does not trigger a mandatory offer obligation under Rule 26 of the Takeovers Code on the part of the holder(s) of the convertible preference shares and parties acting in concert with any of them; and (ii) the public float of the Shares does not fall below the minimum public float requirements stipulated under the GEM Listing Rules or as required by the Stock Exchange. Save as Mr. Yung being a director of Easeglory, none of the Director is a director or employee of Easeglory.

- Marshal as vendor and KC Yung as purchaser have entered into an agreement before the Latest Practicable Date for sale and purchase of the entire shareholding of Easeglory and the completion of the said sale and purchase has been scheduled to a date after the Latest Practicable Date.

3. New Hope International (Hong Kong) Limited is interested in 343,217,539 Shares of the Company. The issued share capital of New Hope International (Hong Kong) Limited is 75% beneficially owned by South Hoper Industry Co. Ltd.# (南方希望實業有限公司) which is in turn 51% held by New Hope Group Co. Ltd.# (新希望集團有限公司) and 49% is held by Tibet Hengyefeng Industrial Co., Ltd.# (西藏恒業峰實業有限公司).

Both New Hope Group Co. Ltd.# (新希望集團有限公司) and Tibet Hengyefeng Industrial Co., Ltd.# (西藏恒業峰實業有限公司) are beneficially held by Mr. Liu Yonghao, Ms. Liu Chang and Ms. Li Wei in shareholding proportionate among them as 62.34%, 36.35% and 1.31% respectively. Therefore, Mr. Liu Yonghao, Ms. Liu Chang and Ms. Li Wei are interested in shares of the Company.

On the basis of the current shareholdings of above Shareholders, an exercise of the Repurchase Mandate in full may result in them becoming obliged to make a mandatory offer under Rule 26 of the Takeovers Code. The Directors have no intention to exercise the Repurchase Mandate to such an extent that will result in a requirement of the above Shareholders, or any other persons to make a general offer under the Takeovers Code. However, the Company may not repurchase Shares which would result in the number of Shares held by the public being reduced to less than 25 per cent.

The GEM Listing Rules prohibit the Company from knowingly purchasing its securities on GEM from a “connected person”, that is, a director, chief executive or substantial shareholder of the Company or any of its subsidiaries or their respective associates.

None of the Directors nor, to the best of their knowledge, having made all reasonable enquiries, any of their associates (as defined in the GEM Listing Rules) have any present intention to sell Shares to the Company or its subsidiaries under the Repurchase Mandate if such is approved by the Shareholders.

No connected person (as defined in the GEM Listing Rules) of the Company has notified the Company that it has a present intention to sell Shares to the Company or its subsidiaries, or has undertaken not to do so, in the event that the Repurchase Mandate is approved by the Shareholders.

9. SHARE REPURCHASE MADE BY THE COMPANY

No Shares had been repurchased by the Company, whether on the GEM or otherwise, in the last six months prior to the Latest Practicable Date.

Set out below are details of the Directors who are proposed to be re-elected at the AGM:

1. Mr. Yung Ka Chun (“ Mr. KC Yung”)

Mr. KC Yung, aged 26, obtained his master degree of science in business majoring in accounting from the University of Maryland, College Park in the United States. Mr. KC Yung was appointed as an executive director of Wanjia Group Holdings Limited (Stock Code: 401), a subsidiary of the Company and the issued shares of which were listed on the Main Board of the Stock Exchange, on 10 October 2014 and he resigned as the executive director of Wanjia Group Holdings Limited on 20 April 2015 (both dates inclusive).

Mr. KC Yung has been appointed as the executive Director and authorised representative of the Company with effective from 20 April 2015. He has entered into a service contract with the Company dated 20 April 2015 for a term of 3 years commencing from the date of the service contract. Mr. KC Yung is entitled to a monthly salary of HK\$50,000 which is determined by the remuneration committee of the Company with reference to his duties and responsibilities at the Company. Mr. KC Yung’s appointment is subject to retirement by rotation and/or re-election at general meeting in accordance with the articles of association of the Company.

Mr. KC Yung is the son of Mr. KL Yung, who is an indirect controlling shareholder of the Company.

As at the Latest Practicable Date, Mr. KC Yung is interested in 2,640,000 Shares and share options, carrying rights to subscribe for 3,960,000 shares at the exercise price of HK\$0.68 per Share during the exercise period from 18 April 2015 to 17 April 2018 under the Share Option Scheme. Save as disclosed herein, Mr. KC Yung does not have any other interests in the Shares or underlying Shares within the meaning of Part XV of the SFO. Mr. KC Yung, other than being the son of Mr. KL Yung, is not connected with any Directors, senior management, management Shareholders, substantial Shareholders or controlling Shareholders of the Company (within the meaning the GEM Listing Rules). Mr. KC Yung is also directors of 23 wholly and non-wholly owned subsidiaries of the Company. Save as disclosed, Mr. KC Yung did not hold any other positions in the Company or any of its subsidiaries and save as disclosed above, did not hold any directorships in any other listed public companies in the past three years.

Save as disclosed above, there is no other matter about Mr. KC Yung which is required to be disclosed pursuant to paragraphs (h) to (v) of Rule 17.50(2) of the GEM Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders.

2. Dr. Wong Yu Man, James (“Dr. Wong”)

Dr. Wong, aged 61, holds two bachelor degrees in medicine and surgery from the University of Hong Kong. Dr. Wong also holds a doctorate degree in medicine from Freiburg University in Germany. He has around 30 years of experience in medical and healthcare services in Hong Kong.

Dr. Wong has been appointed as a non-executive Director by way of letter of appointment with the Company for a period of one year commencing from 20 March 2007 which will continue thereafter until terminated by either party giving not less than one month notice in writing. Dr. Wong is entitled to a fixed emolument of HK\$120,000 per annum which was determined by arm’s length negotiation between Dr. Wong and the Company. Dr. Wong is also entitled to a year-end discretionary bonus to be determined by the Board from time to time. Such salaries and benefits were determined with reference to his roles and responsibilities at the Group and the prevailing market conditions. Dr. Wong is subject to the rotational and retirement requirement under the Articles.

As at the Latest Practicable Date, Dr. Wong was interested in Options, carrying rights to subscribe for 1,000,000 Shares at the exercise price of HK\$0.68 per Share during the exercise period from 18 April 2015 to 17 April 2018 under the Share Option Scheme. Save as disclosed herein, Dr. Wong does not have any interest in the Shares or underlying Shares within the meaning of Part XV of the SFO. Dr. Wong is not connected with any Directors, senior management, management Shareholders, substantial Shareholders or controlling Shareholders of the Company (within the meaning of the GEM Listing Rules). Dr. Wong is a director of a non-wholly owned subsidiary of the Company. Save as disclosed, Dr. Wong did not hold any other position in the Company or any of its subsidiaries and did not hold any directorships in any other listed public companies in the past three years.

Save as disclosed above, there is no matter about Dr. Wong which is required to be disclosed pursuant to paragraphs (h) to (v) of Rules 17.50(2) of the GEM Listing Rules nor are there other matters that need to be brought to the attention of the Shareholders of the Company.

3. Mr. Tang Xun (“Mr. Tang”)

Mr. Tang, aged 33, holds a Bachelor’s degree in Japanese from the Beijing International Studies University (北京第二外國語學院) in 2004, and thereafter a Master’s degree in political economics from Graduate School of Peking University (北京大學) as an on-job postgraduate student in 2012. Mr. Tang Xun has over three years of experience in private equity investment, and is currently an executive director of Beijing Hosen Investment Management, LLP. (北京厚生投資管理中心(有限合夥)). Mr. Tang was appointed as the non-executive director of the Company with effect from 10 March 2015.

On 10 March 2015, the Company entered into a letter of appointment with Mr. Tang, pursuant to which Mr. Tang shall hold office until the next annual general meeting of the Company and thereafter shall be subject to retirement by rotation and re-election at the Company’s annual general meeting in accordance with the articles of association of the Company. Mr. Tang is entitled to a director’s fee of HK\$5,000 per month which is determined by arm’s length negotiation between Mr. Tang and the Company and with reference to his duties and responsibilities. The amount of the remuneration has been approved by the Board and the remuneration committee of the Company.

As at the Latest Practicable Date, Mr. Tang was interested in Options, carrying rights to subscribe for 3,000,000 Shares at the exercise price of HK\$0.68 per Share during the exercise period from 18 April 2015 to 17 April 2018 under the Share Option Scheme. Save as disclosed herein, Mr. Tang does not have any interest in the Shares or underlying Shares within the meaning of Part XV of the SFO. Mr. Tang is not connected with any Directors, senior management, management Shareholders, substantial Shareholders or controlling Shareholders of the Company (within the meaning of the GEM Listing Rules). Save as disclosed, Mr. Tang did not hold any other position in the Company or any of its subsidiaries and did not hold any directorships in any other listed public companies in the past three years.

Save as disclosed above, there is no other information required to be disclosed pursuant to any of the requirements of Rule 17.50(2)(h) to (v) of the GEM Listing Rules and there are no other matters that need to be brought to the attention of the Shareholders of the Company.

NOTICE OF ANNUAL GENERAL MEETING



HUA XIA HEALTHCARE HOLDINGS LIMITED

華夏醫療集團有限公司*

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 8143)

NOTICE IS HEREBY GIVEN THAT the annual general meeting (“AGM”) of the shareholders (“Shareholders”) of Hua Xia Healthcare Holdings Limited (the “Company”) will be held at 19/F., New Wing, 101 King’s Road, Hong Kong on Monday, 17 August 2015, at 3:30 p.m. for the following purposes:

1. to receive and consider the audited financial statements and the reports of the directors and auditors of the Company and its subsidiaries for the year ended 31 March 2015;
2. to re-elect the retiring directors of the Company (“Directors”), namely Mr. Yung Ka Chun, Dr. Wong Yu Man, James and Mr. Tang Xun;
3. to authorise the board of Directors (the “Board”) to fix the remunerations of the Directors;
4. to re-appoint HLB Hodgson Impey Cheng Limited as the auditors of the Company and to authorise the Board to fix their remuneration; and

As special business, to consider and, if thought fit, pass with or without amendments the following proposed resolutions numbered 5 to 8 as ordinary resolutions:

ORDINARY RESOLUTIONS

5. **THAT:**
 - (a) subject to paragraph (c) of this resolution, and pursuant to the Rules Governing the Listing of Securities on The Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”), the exercise by the Directors during the Relevant Period (as hereinafter defined) of all the powers of the Company and to allot, issue and deal with additional shares (“Shares”) in the capital of the Company and to make or grant offers, agreements and options (including bonds, notes, warrants, debentures and securities convertible into Shares) which might require the exercise of such powers be and the same is hereby generally and unconditionally approved;

* For identification purpose only

NOTICE OF ANNUAL GENERAL MEETING

- (b) the approval in paragraph (a) of this resolution shall authorise the Directors during the Relevant Period to make or grant offers, agreements and options which might require the exercise of such powers after the end of the Relevant Period;

- (c) the aggregate nominal amount of share capital allotted or agreed conditionally or unconditionally to be allotted (whether pursuant to options or otherwise) by the Directors pursuant to the approval in paragraph (a) of this resolution, otherwise than pursuant to (i) a Rights Issue (as defined below); or (ii) the grant or exercise of any option under the Share Option Scheme (as defined below) or any other option scheme or similar arrangement of the Company for the time being adopted for the grant or issue to officers and/or employees of the Company and/or any of its subsidiaries of Shares or rights to acquire Shares of the Company; or (iii) any scrip dividend or similar arrangement providing for the allotment of Shares in lieu of the whole or part of a dividend on Shares in accordance with the Articles of Association of the Company in force from time to time; or (iv) any issue of Shares in the Company upon the exercise of rights of subscription or conversion under the terms of any existing warrants of the Company or any existing securities of the Company which carry rights to subscribe for are convertible into Shares of the Company, shall not exceed the aggregate of:
 - (i) 20% of the aggregate nominal amount of the share capital of the Company in issue on the date of the passing of this Resolution; and

 - (ii) (if the Directors are so authorised by a separate ordinary resolution of the shareholders of the Company) the nominal amount of any share capital of the Company repurchased by the Company subsequent to the passing of this resolution (up to a maximum equivalent to 10% of the aggregate nominal amount of the share capital of the Company in issue on the date of the passing of this resolution).

and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and

NOTICE OF ANNUAL GENERAL MEETING

- (d) for the purpose of this resolution:
- (aa) “**Relevant Period**” means the period from the date of the passing of this resolution until whichever is the earliest of:
- (i) the conclusion of the next annual general meeting of the Company;
 - (ii) the expiration of the period within which the next annual general meeting of the Company is required by the Memorandum and Articles of Association of the Company, or any other applicable laws of the Cayman Islands to be held; and
 - (iii) the passing of an ordinary resolution by the shareholders of the Company in general meeting revoking or varying the authority given to the Directors by this resolution.
- (bb) “**Rights Issue**” means an offer of shares in the Company, or offer or issue of warrants, options or other securities giving rights to subscribe for Shares open for a period fixed by the Directors to holders of shares in the Company on the register on a fixed record date in proportion to their holdings of Shares (subject to such exclusion and arrangements as the Directors may deem necessary or expedient in relation to fractional entitlements, or having regard to any restrictions or obligations under the laws of, or the requirements of, or the expenses or delay which may be involved in determining the existence or extent of any restrictions or obligations under the laws of, or the requirements of, any jurisdiction applicable to the Company, or any recognized regulatory body or any stock exchange applicable to the Company).

NOTICE OF ANNUAL GENERAL MEETING

6. **THAT:**

- (a) subject to paragraph (b) of this resolution, the exercise by the Directors during the Relevant Period (as defined in resolution 5(d)(aa)) of all powers of the Company to purchase its shares on the GEM or any other stock exchange on which the shares of the Company may be listed and recognised by the Securities and Futures Commission of Hong Kong (“SFC”) and the Stock Exchange for such purpose, and otherwise in accordance with the rules and regulations of the SFC, the Stock Exchange or any other stock exchange as amended from time to time and all applicable laws in this regard, be and the same is hereby generally and unconditionally approved;
- (b) the aggregate nominal amount of Shares which may be purchased by the Company pursuant to the approval in paragraph (a) of this resolution during the Relevant Period shall not exceed 10% of the aggregate nominal amount of the issued share capital of the Company as at the date of the passing of this resolution and the authority pursuant to paragraph (a) of this resolution shall be limited accordingly; and
- (c) for the purpose of this resolution, “Relevant Period” shall have the same meaning as in resolution no. 5(d)(aa).

7. **THAT** conditional upon resolutions numbered 5 and 6 of this notice being passed, the general mandate granted to the Directors to allot, issue and deal with additional Shares pursuant to resolution numbered 5 be and is hereby extended by the addition thereto of an amount representing the aggregate nominal amount of Shares in the capital of the Company which are repurchased by the Company under the authority granted to the Directors pursuant to resolution numbered 6, provided that the amount of Shares so repurchased by the Company shall not exceed 10% of the aggregate nominal amount of the issued share capital of the Company as at the date of the passing of this resolution.

NOTICE OF ANNUAL GENERAL MEETING

8. “**THAT** subject to and conditional upon the granting by the Listing Committee of the Stock Exchange of, the listing of and permission to deal in, the Shares to be issued pursuant to the exercise of options granted under the refreshed scheme mandate limit (the “Scheme Mandate Limit”) under the share option scheme adopted by the Company on 10 August 2011 in the manner as set out in paragraph (a) of this resolution below,
- (a) the refreshment of the Scheme Mandate Limit of up to 10% of the Shares in issue as at the date of passing of this resolution be and is hereby approved; and
- (b) the Directors be and are hereby authorized do all such acts and things (including but not limited to allotment, issue and dealing with Shares pursuant to the exercise of options granted under the Share Option Scheme within the Scheme Mandate Limit) and execute all such documents, including under seal where applicable, as they consider necessary or expedient to give effect to the foregoing arrangement.”

By Order of the Board
Jiang Tao
Chief Executive Officer

Hong Kong, 23 July 2015

Registered office:

Cricket Square
Hutchins Drive
P.O. Box 2681
Grand Cayman KY1-1111
Cayman Islands

*Head office and principal place of
business in Hong Kong:*

19th Floor, New Wing
101 King’s Road
Hong Kong

NOTICE OF ANNUAL GENERAL MEETING

Notes:

1. A member entitled to attend and vote at the AGM is entitled to appoint one or more proxies to attend and, subject to the provisions of the articles of association of the Company, to vote on his/her/its behalf. A proxy needs not be a member of the Company but must be present in person at the AGM to represent the member. If more than one proxy is so appointed, the appointment shall specify the number and class of Shares in respect of which each such proxy is so appointed.
2. A form of proxy for use at the AGM is enclosed with the circular of the Company dated 23 July 2015. Whether or not you intend to attend the AGM in person, you are encouraged to complete and return the enclosed form of proxy in accordance with the instructions printed thereon. Completion and return of a form of proxy will not preclude a member from attending in person and voting at the AGM or any adjournment thereof, should he/she/its so wish.
3. In order to be valid, the form of proxy, together with a power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority must be deposited at the Company's principal place of business in Hong Kong at 19/F., New Wing, 101 King's Road, Hong Kong not less than 48 hours before the time appointed for holding the AGM or any adjournment thereof.
4. In the case of joint holders of Shares, any one of such holders may vote at the AGM, either personally or by proxy, in respect of such Shares as if he/she/its was solely entitled thereto, but if more than one such joint holders are present at the AGM personally or by proxy, that one of the said persons so present whose name stands first on the register of members of the Company in respect of such Shares shall alone be entitled to vote in respect thereof.